ATAI Life Sciences Earnings: A Preview

  ATAI Life Sciences (NASDAQ:ATAI) is set to give its latest quarterly earnings report on Monday, 2022-08-15. Here's what investors need to know before the announcement.

 

ATAI Life Sciences (NASDAQ:ATAI) is set to give its latest quarterly earnings report on Monday, 2022-08-15. Here’s what investors need to know before the announcement.

Analysts estimate that ATAI Life Sciences will report an earnings per share (EPS) of $-0.23.

ATAI Life Sciences bulls will hope to hear the company to announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Historical Earnings Performance

Last quarter the company missed EPS by $0.00, which was followed by a 1.98% increase in the share price the next day.

Here’s a look at ATAI Life Sciences’s past performance and the resulting price change:

 

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate -0.24 -0.23 -0.20  
EPS Actual -0.24 -0.62 -0.21 -0.37
Price Change % 1.98% -4.68% -4.44% 4.34%

Stock Performance

Shares of ATAI Life Sciences were trading at $4.43 as of August 11. Over the last 52-week period, shares are down 69.36%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

To track all earnings releases for ATAI Life Sciences visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

CBD of Denver Reports YoY Increase In 2023 Gross Profit, Reduces Loss As It Continues To Expand Internationally

CBD of Denver, Inc. has filed its financial results for the year ended Dec. 31, 2023.The Colorado-based cannabis company said total current assets increased to $117,218 in 2023, up from $28,043 in 2022. Gross profit for the year totaled $595,417, representing a significant recovery from a gross loss of $284,734 in the prior year, due to a 27% increase in sales and a reduction in cost of goods sold. Net income before provision for income tax showed improvement with a loss of $377,729 in 2023, compared to a loss of $3,257,710 in 2022. CBD of Denver attributed it to the company's efforts to enhance operational efficiency and improve cost management.

CBDD